Oritavancin
- Generic Name
- Oritavancin
- Brand Names
- Kimyrsa, Orbactiv, Tenkasi (previously Orbactiv)
- Drug Type
- Small Molecule
- Chemical Formula
- C86H97Cl3N10O26
- CAS Number
- 171099-57-3
- Unique Ingredient Identifier
- PUG62FRZ2E
- Background
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administratio...
- Indication
用于治疗由下列易感分离株革兰氏阳性微生物所致急性细菌皮肤和皮肤结构感染(ABSSSI)成年患者的治疗。如金黄色葡萄球菌(包括甲氧西林-易感和甲氧西林–耐药分离株)，化脓性链球菌，无乳链球菌，停乳链球菌，咽峡炎链球菌群(包括咽颊炎链球菌，中间型链球菌,和星座链球菌)，和粪肠球菌(万古霉素-仅易感分离株)。
- Associated Conditions
- Skin and skin structure infections
- Associated Therapies
- -
A Study for Patients With Complicated Skin and Skin Structure Infections
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Targanta Therapeutics Corporation
- Target Recruit Count
- 294
- Registration Number
- NCT00514527
- Locations
- 🇺🇦
Targanta Recruiting Site, Zaporizhzhya, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath